Gel given orphan drug status in Europe for CTCL
The privately held specialty pharmaceutical company Ceptaris Therapeutics has announced that the European Medicines Agency (EMA) has given Orphan Drug Designation to the company's investigational drug chlormethine gel (known as mechlorethamine gel in the United States) for the treatment of Cutaneous T-Cell Lymphoma (CTCL).
The gel was previously granted orphan drug status in the US by the US Food and Drug Administration.
The FDA is currently reviewing the New Drug Application (NDA) submitted by Ceptaris Therapeutics in July 2011 for mechlorethamine gel for the treatment of early stage favorable mycosis fungoides, a subtype of Cutaneous T-Cell Lymphoma (CTCL).
Source: MarketWatch
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
